Table 1.

List of available works of CMV-specific T-cell transfer in SOT.

Method	Organ and D/R status	Number of infused cells	Number of infusions	Cell line phenotype	Stimulation method	Post-infusion clinical outcomes
Direct selection by IFN-γ capture Brestrich et al. (41)	1 Lung +/+	Fresh 1 × 107 T-cells/m2	2	95% CD3+ cells with 2.7% and 92.3% CD4+ and CD8+ cells. No CD16+ natural killer cells and only 0.1% CD19+ B cells	Overlapping IE-1/pp65 peptide pools	No side effects occurred after the infusion. The number of CMV-specific T-cells increased, while viral load decreased. The patient died from graft failure
Ex vivo expansion from a third party donor (43)	1 Kidney +/−	Frozen 1.6 x107 T-cells/m2	1	16.6% CD4+ and 79.4% CD8+ cells	Overlapping pp65 peptide pool	The patient developed a mild fever but no other adverse effects were noted and within 4 months his CMV viral load decreased from >5×106 copies to 682 copies/mL and remained controlled up to 1 year
Autologous Ex vivo expansion (46)	1 Lung +/−	Fresh 3 × 107 T-cells	4	82.6% CD3+ cells, including 14% CD4+ and 73.8% CD8+ cells	PBMC coated with HLA class I-restricted CMV epitopes	Decrease in viral load. No graft rejection
Autologous Ex vivo expansion (47)	1 Lung +/−	Frozen two of 1.9 x107 cells and one of 22.2 x 106 T-cells	3	Two first infusions 41.6% CD8+ cells Third infusion 4.43% CD8+ cells	HLA Class I restricted epitopes from pp65, pp50 and IE-1	The patient did not have any documented rejection or acute change in lung function after the T-cell infusions but finally died due to clinical complications unrelated to CMV
Autologous Ex vivo expansion (48)	13 kidney, 8 lung and 1 heart +/− +/+ −/−	Frozen 22.2-245 × 106 T-cells	6	20% CD4+ and 70% CD8+ cells	HLA class I– and class II–restricted epitopes from pp65, pp50, IE-1, gH, and gB	None of the patients who received adoptive CMV-specific T-cell therapy showed treatment-related grade 3, 4, or 5 adverse events. Reduction or resolution of CMV reactivation and/or disease and improved response to antiviral drug therapy